tetano
Editor, Senior Moderator
J Eur Acad Dermatol Venereol. 2020 May 7. doi: 10.1111/jdv.16587. [Epub ahead of print]
Evolution of COVID-19 infection in 4 psoriatic patients treated with biological drugs.
Conti A[SUP]1[/SUP], Lasagni C[SUP]1[/SUP], Bigi L[SUP]1[/SUP], Pellacani G[SUP]1[/SUP].
Author information
Abstract
Since December 2019, the pandemic coronavirus disease (2019-nCoV; COVID-19) has changed the approach to all dermatological diseases; in particular, psoriatic patients undergoing immunosuppressive drugs, such as biologics, can potentially show an increase risk of infection (1). However, few reports are available on the course of COVID-19 infection in psoriatic patients treated with biological drugs (2). We describe a case series of four psoriatic patients treated with biologics who had a risk contact with COVID-19.
This article is protected by copyright. All rights reserved.
KEYWORDS:
SARS-CoV-2; covid-19; psoriasis; biologic; therapies
PMID:32379913DOI:10.1111/jdv.16587
Evolution of COVID-19 infection in 4 psoriatic patients treated with biological drugs.
Conti A[SUP]1[/SUP], Lasagni C[SUP]1[/SUP], Bigi L[SUP]1[/SUP], Pellacani G[SUP]1[/SUP].
Author information
Abstract
Since December 2019, the pandemic coronavirus disease (2019-nCoV; COVID-19) has changed the approach to all dermatological diseases; in particular, psoriatic patients undergoing immunosuppressive drugs, such as biologics, can potentially show an increase risk of infection (1). However, few reports are available on the course of COVID-19 infection in psoriatic patients treated with biological drugs (2). We describe a case series of four psoriatic patients treated with biologics who had a risk contact with COVID-19.
This article is protected by copyright. All rights reserved.
KEYWORDS:
SARS-CoV-2; covid-19; psoriasis; biologic; therapies
PMID:32379913DOI:10.1111/jdv.16587